{"id":"bulevirtide","rwe":[{"pmid":"41903606","year":"2026","title":"Response-guided bulevirtide ± pegylated interferon alfa-2a: long-term outcomes observed in the nationwide Austrian hepatitis D cohort study.","finding":"","journal":"JHEP reports : innovation in hepatology","studyType":"Clinical Study"},{"pmid":"41882877","year":"2026","title":"Modeling of the hepatitis B virus life cycle and the efficacy of antivirals in human iPSC-derived hepatic organoids.","finding":"","journal":"Bioscience trends","studyType":"Clinical Study"},{"pmid":"41878152","year":"2026","title":"Resolution of Hepatitis Delta Virus-Related Cryoglobulinemic Vasculitis With the Use of Bulevirtide.","finding":"","journal":"ACG case reports journal","studyType":"Clinical Study"},{"pmid":"41861841","year":"2026","title":"Who to test and reflex testing for hepatitis D virus infection: evidence and rationale to inform policy recommendations and future directions.","finding":"","journal":"The lancet. Gastroenterology & hepatology","studyType":"Clinical Study"},{"pmid":"41861840","year":"2026","title":"How to test for hepatitis D virus infection: evidence and rationale to inform policy recommendations and future directions.","finding":"","journal":"The lancet. Gastroenterology & hepatology","studyType":"Clinical Study"}],"tags":[{"label":"Biologic","category":"modality"},{"label":"Sodium/bile acid cotransporter","category":"target"},{"label":"SLC10A1","category":"gene"},{"label":"J05AX28","category":"atc"},{"label":"Active","category":"status"},{"label":"Chronic infection caused by Hepatitis D virus","category":"indication"},{"label":"Chronic viral hepatitis B with hepatitis D","category":"indication"},{"label":"MYR GmbH","category":"company"}],"phase":"marketed","safety":{},"trials":[],"aliases":[],"company":"MYR GmbH","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=BULEVIRTIDE","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T03:29:07.981322+00:00"},"timeline":{"url":"https://en.wikipedia.org/wiki/Bulevirtide","method":"deterministic","source":"Wikipedia","rawText":"","confidence":0.8,"sourceType":"wikipedia","retrievedAt":"2026-04-20T03:29:14.599866+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T03:29:13.279856+00:00"},"regulatory.eu":{"url":"","method":"api_direct","source":"European Medicines Agency","rawText":"","confidence":1,"sourceType":"ema_api","retrievedAt":"2026-04-20T03:29:08.055898+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=BULEVIRTIDE","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T03:29:13.476468+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Bile acid transporter inhibitor","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T03:29:14.599796+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL4297711/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T03:29:14.169793+00:00"}},"allNames":"hepcludex","offLabel":[],"synonyms":["bulevirtide","bulevirtide acetate","hepcludex","myrcludex B"],"timeline":[{"date":"2020-07-31","type":"positive","source":"DrugCentral","milestone":"EMA approval (MYR GmbH)"}],"aiSummary":"Hepcludex (Bulevirtide) is a small molecule developed by MYR GmbH, targeting the sodium/bile acid cotransporter. It is approved to treat chronic infections caused by the Hepatitis D virus and chronic viral hepatitis B with hepatitis D. The commercial status of Hepcludex is patented, with MYR GmbH being the current owner. Key safety considerations are not specified. Hepcludex works by inhibiting the sodium/bile acid cotransporter, which is involved in the replication of the Hepatitis D virus.","brandName":"Hepcludex","ecosystem":[{"indication":"Chronic infection caused by Hepatitis D virus","otherDrugs":[],"globalPrevalence":68500000},{"indication":"Chronic viral hepatitis B with hepatitis D","otherDrugs":[],"globalPrevalence":296000000}],"mechanism":{"target":"Sodium/bile acid cotransporter","targets":[{"gene":"SLC10A1","source":"DrugCentral","target":"Sodium/bile acid cotransporter","protein":"Sodium/bile acid cotransporter"}],"modality":"Peptide","explanation":"","oneSentence":"","technicalDetail":"Hepcludex specifically inhibits the sodium/bile acid cotransporter (NTCP), which is the primary receptor for the Hepatitis D virus. By blocking NTCP, Hepcludex prevents the virus from entering liver cells and replicating, ultimately reducing liver inflammation and damage."},"_wikipedia":{"url":"https://en.wikipedia.org/wiki/Bulevirtide","title":"Bulevirtide","extract":"Bulevirtide, sold under the brand name Hepcludex, is an antiviral medication used for the treatment of chronic hepatitis D."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/5417","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=BULEVIRTIDE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=BULEVIRTIDE","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://en.wikipedia.org/wiki/Bulevirtide","fields":["history","overview"],"source":"Wikipedia"}],"_emaChecked":true,"_enrichedAt":"2026-03-30T09:04:00.116851","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T03:29:15.809730+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"enfuvirtide","drugSlug":"enfuvirtide","fdaApproval":"2003-03-13","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"maraviroc","drugSlug":"maraviroc","fdaApproval":"2007-08-06","genericCount":4,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"maribavir","drugSlug":"maribavir","fdaApproval":"2021-11-23","patentExpiry":"Oct 27, 2031","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"letermovir","drugSlug":"letermovir","fdaApproval":"2017-11-08","patentExpiry":"Jan 18, 2029","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"ibalizumab","drugSlug":"ibalizumab","fdaApproval":"2018-03-06","relationship":"same-class"},{"drugName":"tecovirimat","drugSlug":"tecovirimat","fdaApproval":"2018-07-13","patentExpiry":"Sep 4, 2031","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"baloxavir marboxil","drugSlug":"baloxavir-marboxil","fdaApproval":"2018-10-24","patentExpiry":"Sep 25, 2038","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"fostemsavir","drugSlug":"fostemsavir","fdaApproval":"2020-07-02","patentExpiry":"Nov 19, 2027","patentStatus":"Patent protected","relationship":"same-class"}],"genericName":"bulevirtide","indications":{"approved":[{"name":"Chronic infection caused by Hepatitis D virus","source":"DrugCentral","snomedId":735451005,"regulator":"FDA","globalPrevalence":68500000,"prevalenceMethod":"ai-extracted","prevalenceSource":"Gut, 2019 (PMID:30228220)"},{"name":"Chronic viral hepatitis B with hepatitis D","source":"DrugCentral","snomedId":235869004,"regulator":"FDA","usPrevalence":880000,"globalPrevalence":296000000,"prevalenceMethod":"curated","prevalenceSource":"WHO, 2024"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"enfuvirtide","brandName":"enfuvirtide","genericName":"enfuvirtide","approvalYear":"2003","relationship":"same-class"},{"drugId":"maraviroc","brandName":"maraviroc","genericName":"maraviroc","approvalYear":"2007","relationship":"same-class"},{"drugId":"maribavir","brandName":"maribavir","genericName":"maribavir","approvalYear":"2021","relationship":"same-class"},{"drugId":"letermovir","brandName":"letermovir","genericName":"letermovir","approvalYear":"2017","relationship":"same-class"},{"drugId":"ibalizumab","brandName":"ibalizumab","genericName":"ibalizumab","approvalYear":"2018","relationship":"same-class"},{"drugId":"tecovirimat","brandName":"tecovirimat","genericName":"tecovirimat","approvalYear":"2018","relationship":"same-class"},{"drugId":"baloxavir-marboxil","brandName":"baloxavir marboxil","genericName":"baloxavir marboxil","approvalYear":"2018","relationship":"same-class"},{"drugId":"fostemsavir","brandName":"fostemsavir","genericName":"fostemsavir","approvalYear":"2020","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT07200908","phase":"PHASE3","title":"A Trial Evaluating Brelovitug (BJT-778) vs Bulevirtide for the Treatment of Chronic Hepatitis Delta Infection (AZURE-2)","status":"RECRUITING","sponsor":"Mirum Pharmaceuticals, Inc.","startDate":"2025-08-27","conditions":["Chronic Hepatitis D Infection"],"enrollment":172,"completionDate":"2029-09-30"},{"nctId":"NCT07491848","phase":"","title":"Oral-Periodontal Evaluation and Assessment of Oral Fluid Biomarkers in Patients With Hepatitis B+D","status":"RECRUITING","sponsor":"Research Center of Periodontal-Systemic Interactions","startDate":"2026-02-15","conditions":["HEPATITIS B CHRONIC","Hepatitis D","Periodontitis"],"enrollment":25,"completionDate":"2027-02-15"},{"nctId":"NCT06780579","phase":"","title":"Expanded Access for Bulevirtide","status":"AVAILABLE","sponsor":"Gilead Sciences","startDate":"","conditions":["Chronic Hepatitis Delta Virus Infection"],"enrollment":0,"completionDate":""},{"nctId":"NCT07454837","phase":"PHASE2,PHASE3","title":"Phase 2b/3 Study to Evaluate Switching to Brelovitug for the Treatment of CHD in Participants Receiving Bulevirtide","status":"RECRUITING","sponsor":"Mirum Pharmaceuticals, Inc.","startDate":"2026-02-26","conditions":["Chronic Hepatitis D"],"enrollment":120,"completionDate":"2029-03-30"},{"nctId":"NCT07128550","phase":"PHASE3","title":"A Study to Evaluate Tobevibart+Elebsiran in Participants With Chronic HDV Infection Not Virologically Suppressed With Bulevirtide","status":"RECRUITING","sponsor":"Vir Biotechnology, Inc.","startDate":"2025-07-30","conditions":["Viral Hepatitis"],"enrollment":150,"completionDate":"2031-07"},{"nctId":"NCT06603311","phase":"NA","title":"Finite Treatment of Hepatitis Delta With Bulevirtide: Identification of Biomarkers Associated With Sustained Control of HDV Infection","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hannover Medical School","startDate":"2024-09-30","conditions":["Compensated Liver Disease (Disorder)","Hepatitis D, Chronic"],"enrollment":20,"completionDate":"2026-06-30"},{"nctId":"NCT07429864","phase":"","title":"Changes in Bile Acids and Microbiota in Patients With Hepatitis D Treated With Bulvertide","status":"RECRUITING","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2025-09-24","conditions":["HBV","HBV Coinfection","HCV","HIV Infections","Hepatocellular Carcinoma","Cirrhosis, Liver","Fibrosis, Liver","Bile Acid Malabsorption","Microbial Colonization"],"enrollment":20,"completionDate":"2027-10"},{"nctId":"NCT05765344","phase":"PHASE1","title":"Study of Bulevirtide in Participants Who Have Normal or Impaired Liver Function","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2023-03-15","conditions":["Hepatic Impairment","Healthy"],"enrollment":74,"completionDate":"2025-01-13"},{"nctId":"NCT07313358","phase":"","title":"10119473 -VIROMARKERS HDV Biomarkers Study","status":"NOT_YET_RECRUITING","sponsor":"University of Rome Tor Vergata","startDate":"2026-02-20","conditions":["HDV Infection"],"enrollment":220,"completionDate":"2026-10-30"},{"nctId":"NCT07142811","phase":"PHASE2","title":"A Study to Evaluate Tobevibart+Elebsiran Versus Bulevirtide in Chronic HDV Infection","status":"ACTIVE_NOT_RECRUITING","sponsor":"Vir Biotechnology, Inc.","startDate":"2025-08-05","conditions":["Viral Hepatitis"],"enrollment":100,"completionDate":"2030-07"},{"nctId":"NCT06372990","phase":"","title":"Rapid T-cell Analysis Test in Patients With Chronic HBV and HBV/HDV Disease","status":"RECRUITING","sponsor":"Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico","startDate":"2024-04-15","conditions":["HBV","HBV/HDV"],"enrollment":300,"completionDate":"2026-09-30"},{"nctId":"NCT06504485","phase":"","title":"Immunological and Virological Characterization of Patients With Chronic HBV-HDV Infection: Outcomes and Response to Bulevirtide Treatment","status":"RECRUITING","sponsor":"Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico","startDate":"2024-09-01","conditions":["Hepatitis D"],"enrollment":192,"completionDate":"2026-02-28"},{"nctId":"NCT05718700","phase":"","title":"Study of Bulevirtide in Participants With Chronic Hepatitis D Infection","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2023-02-07","conditions":["Chronic Hepatitis D Infection"],"enrollment":170,"completionDate":"2028-07"},{"nctId":"NCT05760300","phase":"PHASE1","title":"A Multiple-Dose Study of Bulevirtide in Participants With Normal and Impaired Renal Function","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2023-03-15","conditions":["Chronic Hepatitis D Infection"],"enrollment":41,"completionDate":"2024-07-23"},{"nctId":"NCT04863703","phase":"","title":"Improvement of Portal Hypertension During Viral Suppression in Patients With Hepatitis Delta (IMPHROVE-D)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hannover Medical School","startDate":"2021-05-07","conditions":["Hepatitis D","Hepatitis B","Portal Hypertension","Liver Cirrhosis"],"enrollment":11,"completionDate":"2026-12-31"},{"nctId":"NCT03852719","phase":"PHASE3","title":"Study to Assess Efficacy and Safety of Bulevirtide in Participants With Chronic Hepatitis Delta (CHD)","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2019-04-17","conditions":["Chronic Hepatitis Delta"],"enrollment":150,"completionDate":"2024-08-08"},{"nctId":"NCT07116044","phase":"","title":"Assessment of Response and Safety of Bulevirtide Treatment in Patients With Chronic Delta Virus Infection","status":"COMPLETED","sponsor":"University of Molise","startDate":"2023-06-15","conditions":["Evaluate Response to Treatment Both Biochemically and Virologically to Determine the Safety and Effectiveness of Bulevirtide Therapy in HDV Patients"],"enrollment":160,"completionDate":"2025-07-30"},{"nctId":"NCT06121427","phase":"","title":"Incidence of Viral Hepatitis D Relapses Upon Discontinuation of Bulevirtide in Patients With Chronic Hepatitis D and Negative HDV RNA","status":"COMPLETED","sponsor":"Center of target therapy","startDate":"2023-09-01","conditions":["Chronic Hepatitis D"],"enrollment":24,"completionDate":"2025-02-28"},{"nctId":"NCT06122285","phase":"","title":"Effectiveness and Safety of Bulevirtide (BLV) Therapy in Patients With Chronic Hepatitis Delta (CHD) in Italy (D-SHIELD)","status":"RECRUITING","sponsor":"Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico","startDate":"2023-05-01","conditions":["Hepatitis D"],"enrollment":100,"completionDate":"2025-12-31"},{"nctId":"NCT03852433","phase":"PHASE2","title":"Study to Assess Efficacy and Safety of Bulevirtide in Combination With Pegylated Interferon Alfa-2a in Participants With Chronic Hepatitis Delta (CHD)","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2019-05-31","conditions":["Chronic Hepatitis Delta"],"enrollment":175,"completionDate":"2022-09-28"},{"nctId":"NCT06397859","phase":"","title":"Effectiveness and Clinical Outcomes of Long-term Bulevirtide Monotherapy in Patients With HDV-related Compensated Cirrhosis","status":"RECRUITING","sponsor":"Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico","startDate":"2024-05-06","conditions":["Hepatitis D"],"enrollment":266,"completionDate":"2026-08-31"},{"nctId":"NCT06051045","phase":"","title":"Study to Evaluate Efficacy, Safety and Biomarkers of Bulevirtide Treatment in Chronic Hepatitis D Patients","status":"RECRUITING","sponsor":"Karolinska University Hospital","startDate":"2023-09-27","conditions":["Chronic Hepatitis D"],"enrollment":400,"completionDate":"2033-03"},{"nctId":"NCT05962307","phase":"","title":"Efficacy and Safety of Bulevirtide (BLV) Therapy in HDV Chronic Hepatitis (CHD) in Italy","status":"COMPLETED","sponsor":"Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico","startDate":"2023-04-01","conditions":["Hepatitis D"],"enrollment":50,"completionDate":"2023-05-31"},{"nctId":"NCT05928000","phase":"","title":"HEllenic Multicenter ReAl-life CLInical Study for Bulevirtide Therapy in Chronic Hepatitis D: HERACLIS-BLV","status":"UNKNOWN","sponsor":"University of Athens","startDate":"2023-05-01","conditions":["Hepatitis D"],"enrollment":80,"completionDate":"2023-12-30"},{"nctId":"NCT02888106","phase":"PHASE2","title":"Myrcludex B in Combination With Peginterferon Alfa-2a Versus Peginterferon Alfa-2a Alone in Patients With Chronic Viral Hepatitis B With Delta-agent","status":"COMPLETED","sponsor":"Hepatera Ltd.","startDate":"2016-04","conditions":["Chronic Viral Hepatitis B With Delta-agent"],"enrollment":90,"completionDate":"2020-10-30"}],"_emaApprovals":[{"date":"2020-07-31","status":"Authorised","company":"MYR GmbH"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"NDDF":"019120","UNII":"WKM56H3TLB","INN_ID":"10692","UMLSCUI":"C5139876","chemblId":"CHEMBL4297711","ChEMBL_ID":"CHEMBL4297711","KEGG_DRUG":"D11877","DRUGBANK_ID":"DB15248","IUPHAR_LIGAND_ID":"12775","SECONDARY_CAS_RN":"406461-66-3","MESH_SUPPLEMENTAL_RECORD_UI":"C571888"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"present","companyName":"MYR GmbH","relationship":"Current Owner"}],"publicationCount":205,"therapeuticAreas":["Infectious Disease"],"atcClassification":{"source":"DrugCentral","atcCode":"J05AX28","allCodes":["J05AX28"]},"biosimilarFilings":[],"recentPublications":[{"date":"2026 Mar 26","pmid":"41903606","title":"Response-guided bulevirtide ± pegylated interferon alfa-2a: long-term outcomes observed in the nationwide Austrian hepatitis D cohort study.","journal":"JHEP reports : innovation in hepatology"},{"date":"2026 Mar 26","pmid":"41882877","title":"Modeling of the hepatitis B virus life cycle and the efficacy of antivirals in human iPSC-derived hepatic organoids.","journal":"Bioscience trends"},{"date":"2026 Mar","pmid":"41878152","title":"Resolution of Hepatitis Delta Virus-Related Cryoglobulinemic Vasculitis With the Use of Bulevirtide.","journal":"ACG case reports journal"},{"date":"2026 Mar 17","pmid":"41861841","title":"Who to test and reflex testing for hepatitis D virus infection: evidence and rationale to inform policy recommendations and future directions.","journal":"The lancet. Gastroenterology & hepatology"},{"date":"2026 Mar 17","pmid":"41861840","title":"How to test for hepatitis D virus infection: evidence and rationale to inform policy recommendations and future directions.","journal":"The lancet. Gastroenterology & hepatology"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"MYR GmbH","companyId":"myr-gmbh","modality":"Recombinant protein","firstApprovalDate":"","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"EU","regulator":"EMA","status":"pending","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":9,"withResults":3},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T03:29:15.809730+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}